Dendritic cell inhibition correlates with survival of colorectal cancer patients on bevacizumab treatment

OncoImmunology

Volumn 1, Issue 8, 2012, Pages 1445-1447

  Michielsen, Adriana J ^a   Ryan, Elizabeth J ^b   O'Sullivan, Jacintha N ^a  

^a ST JAMES S HOSPITAL   (Ireland)

^b ST VINCENT S UNIVERSITY HOSPITAL   (Ireland)

Author keywords

Bevacizumab; Colorectal cancer; Dendritic cells; Tumor microenvironment

Indexed keywords

B7 ANTIGEN; BEVACIZUMAB; CD1D ANTIGEN; CD83 ANTIGEN; CD86 ANTIGEN; GLYCOPROTEIN P 15095; HLA DR ANTIGEN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 12P70; LIPOPOLYSACCHARIDE; VASCULOTROPIN;

ANTIGEN PRESENTING CELL; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CELL INFILTRATION; CELL MATURATION; COLORECTAL CANCER; CYTOKINE RELEASE; DENDRITIC CELL; HUMAN; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; LYMPHOCYTE ACTIVATION; NOTE; PRIORITY JOURNAL; PROTEIN SYNTHESIS INHIBITION; TH1 CELL; TREATMENT RESPONSE; TUMOR MICROENVIRONMENT;

EID: 84876872556     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/onci.21318     Document Type: Note

References (9)

1. Siegel R, Desantis C, Virgo K, Stein K, Mariotto A, Smith T, et al. Cancer treatment and survivorship statistics, 2012. [n/a-n/a.]. CA Cancer J Clin 2012; •••:2012; PMID:22700443.
2. Labianca R, Beretta GD, Kildani B, Milesi L, Merlin F, Mosconi S, et al. Colon cancer. Crit Rev Oncol Hematol 2010; 74:106-33; PMID:20138539; http://dx.doi.org/10.1016/j.critrevonc.2010.01.010.
3. Michielsen AJ, O'Sullivan JN, Ryan EJ. Recent Advances in the Development of Novel Therapeutics Targeting Dendritic Cells. Recent Pat Endocr Metab Immune Drug Discov 2010; 4:146-52; http://dx.doi. org/10.2174/187221410791196650.
4. Minkis K, Kavanagh DG, Alter G, Bogunovic D, O'Neill D, Adams S, et al. Type 2 Bias of T cells expanded from the blood of melanoma patients switched to type 1 by IL-12p70 mRNA-transfected dendritic cells. Cancer Res 2008; 68:9441-50; PMID:19010919; http://dx.doi.org/10.1158/0008-5472.CAN-08-0900.
5. Xu S, Koski GK, Faries M, Bedrosian I, Mick R, Maeurer M, et al. Rapid high efficiency sensitization of CD8+ T cells to tumor antigens by dendritic cells leads to enhanced functional avidity and direct tumor recognition through an IL-12-dependent mechanism. J Immunol 2003; 171:2251-61; PMID:12928369.
6. Godfrey DI, Stankovic S, Baxter AG. Raising the NKT cell family. Nat Immunol 2010; 11:197-206; PMID:20139988; http://dx.doi.org/10.1038/ni.1841.
7. Michielsen AJ, Noonan S, Martin P, Tosetto M, Marry J, Biniecka M, et al. Inhibition of dendritic cell maturation by the tumour microenvironment correlates with the survival of colorectal cancer patients following Bevacizumab treatment. Mol Cancer Ther 2012; PMID:22675042; http://dx.doi.org/10.1158/1535-7163.MCT-12-0162.
8. O'Sullivan JN, Bronner MP, Brentnall TA, Finley JC, Shen WT, Emerson S, et al. Chromosomal instability in ulcerative colitis is related to telomere shortening. Nat Genet 2002; 32:280-4; PMID:12355086; http://dx.doi.org/10.1038/ng989.
9. Michielsen AJ, Hogan AE, Marry J, Tosetto M, Cox F, Hyland JM, et al. Tumour tissue microenvironment can inhibit dendritic cell maturation in colorectal cancer. PLoS One 2011; 6:e27944; PMID:22125641; http://dx.doi.org/10.1371/journal.pone.0027944.